tbuckley/cabot-search huggingface dataset:
Inflammatory Cytokine Responses in Pediatric tuberculosis with or without SARS-CoV-2 seropositivity
Authors: Nathella Pavan Kumar, Sarath Balaji, Poorna Ganga Devi, Balaji Ramraj, Arul Nancy, Nandhini Selvaraj, Shaik Fayaz Ahamed, Karthik M, Suba S, A Gunasundari, A Seetha, Poovazhagi Varadarajan, Elilarasi S, Aishwarya Venkataraman, Subash Babu
Journal: Journal of Infection (2024)
Dual hypothermic oxygenated machine perfusion of the liver reduces post transplant biliary complications – a retrospective cohort study
Authors: David Pereyra, Jule Dingfelder, Moriz Riha, Sertac Kacar, Laurin Rauter, Nikolaus Becker, Tina Saffarian Zadeh, Chiara Tortopis, Patrick Starlinger, Robin Ristl, Gerd Silberhumer, Andreas Salat, Thomas Soliman, Gabriela Berlakovich, Georg Gyoeri
Journal: International Journal of Surgery (2024)

Corroborating evidence for use of hypothermic oxygenated machine perfusion (HOPE) prior to orthotopic liver transplantation (OLT) suggests a beneficial effect in regards to biliary complications. Here, we aim to evaluate whether perfusion via portal vein alone (sHOPE) or via additional perfusion of the hepatic artery (dHOPE) have diverging impact on outcomes after OLT when compared to use of static cold storage (SCS).
Efficacy of ursodeoxycholic acid for bile reflux after distal gastrectomy in patients with gastric cancer: A secondary analysis of the PEGASUS-D randomized clinical trial
Authors: Dong Kee Jang, Young Suk Park, Moon-Won Yoo, Sun-Hwi Hwang, Seong-Yeob Ryu, Oh Kyoung Kwon, Hoon Hur, Hong Man Yoon, Bang Wool Eom, Hye Seong Ahn, Taeil Son, Kyo Young Song, Han Hong Lee, Min-Gew Choi, Ji Yeong An, Sang-Il Lee, Sang Hyub Lee, Do Joong Park
Journal: International Journal of Surgery (2024)

Background: Few studies have been conducted on the prevention of bile reflux in gastric cancer patients who have undergone gastrectomy. The aim of this study was to evaluate the efficacy and safety of ursodeoxycholic acid (UDCA) in preventing bile reflux after gastrectomy in patients with gastric cancer. Methods: This study was a secondary analysis of the PEGASUS-D trial, a randomized, double-blind, placebo-controlled clinical trial. Adults with a diagnosis of gastric cancer who underwent gastrectomy were enrolled. Eligible participants were randomly assigned to receive 300 mg of UDCA, 600 mg of UDCA, or placebo at a ratio of 1:1:1. UDCA and placebo were administered daily for 52 weeks. The primary outcomes included bile reflux symptoms at each time point, percentage of participants with bile reflux, and the grade of gastritis. Results: Among 521 participants who underwent randomization, 151, 164, and 150 participants were analyzed from the 300 mg UDCA, 600 mg UDCA, and placebo groups, respectively. The difference in symptoms between the three groups was not significant. Bile reflux was less evident in the UDCA group than in the placebo group; however, this difference was significant only in the 300-mg group at 12 months post-operation (odds ratio, 0.44; P = 0.0076). A significant reduction in gastritis was also observed in the 300-mg group at 12 months post-operation (odds ratio, 0.50; P = 0.0368) compared to the placebo group. Conclusions: This study showed that UDCA administration significantly reduced bile reflux and gastritis by approximately 50% at the 12 months-postoperative follow-up in patients who underwent gastrectomy for gastric cancer.
A View of Myeloid Transformation through the Hallmarks of Cancer
Authors: Inés Fernández-Maestre, Sheng F. Cai, Ross L. Levine
Journal: Blood Cancer Discovery (2024)

The development of myeloid malignancies is influenced by a range of cell-intrinsic and cell-extrinsic factors, which can be conceptualized using the hallmarks of cancer. Although many facets of myeloid transformation are similar to those in solid tumors, there are also notable differences. Unlike solid tumors, hematologic malignancies typically exhibit fewer genetic mutations, which have been well characterized. However, understanding the cell-extrinsic factors contributing to myeloid malignancies can be challenging due to the complex interactions in the hematopoietic microenvironment. Researchers need to focus on these intricate factors to prevent the early onset of myeloid transformation and develop appropriate interventions. Significance: Myeloid malignancies are common in the elderly, and acute myeloid leukemia has an adverse prognosis in older patients. Investigating cell-extrinsic factors influencing myeloid malignancies is crucial to developing approaches for preventing or halting disease progression and predicting clinical outcomes in patients with advanced disease. Whereas successful intervention may require targeting various mechanisms, understanding the contribution of each cell-extrinsic factor will help prioritize clinical targets.
Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment
Authors: Deepak Singhal, Monika M. Kutyna, Christopher N. Hahn, Mithun Vinod Shah, Devendra K. Hiwase
Journal: Blood Cancer Discovery (2024)

Therapy-related myeloid neoplasm (t-MN), characterized by its association with prior exposure to cytotoxic therapy, remains poorly understood and is a major impediment to long-term survival even in the era of novel targeted therapies due to its aggressive nature and treatment resistance. Previously, cytotoxic therapy-induced genomic changes in hematopoietic stem cells were considered sine qua non in pathogenesis; however, recent research demonstrates a complex interaction between acquired and hereditary genetic predispositions, along with a profoundly senescent bone marrow (BM) microenvironment. We review emerging data on t-MN risk factors and explore the intricate interplay among clonal hematopoiesis, genetic predisposition, and the abnormal BM microenvironment. Significance: t-MN represents a poorly understood blood cancer with extremely poor survival and no effective therapies. We provide a comprehensive review of recent preclinical research highlighting complex interaction among emerging therapies, hereditary and acquired genetic factors, and BM microenvironment. Understanding the risk factors associated with t-MN is crucial for clinicians, molecular pathologists, and cancer biologists to anticipate and potentially reduce its incidence in the future. Moreover, better understanding of the molecular pathogenesis of t-MN may enable preemptive screening and even intervention in high-risk patients.
Targeted inhibition of Gus-expressing Enterococcus faecalis to promote intestinal stem cell and epithelial renovation contributes to the relief of irinotecan chemotoxicity by dehydrodiisoeugenol
Authors: Ruiyang Gao, Bei Yue, Cheng Lv, Xiaolong Geng, Zhilun Yu, Hao Wang, Beibei Zhang, Fangbin Ai, Ziyi Wang, Donghui Liu, Zhengtao Wang, Kaixian Chen, Wei Dou
Journal: Acta Pharmaceutica Sinica B (2024)

Irinotecan (CPT11) chemotherapy-induced diarrhea affects a substantial cancer population due to β-glucuronidase (Gus) converting 10-O-glucuronyl-7-ethyl-10-hydroxycamptothecin (SN38G) to toxic 7-ethyl-10-hydroxycamptothecin (SN38). Existing interventions primarily address inflammation and Gus enzyme inhibition, neglecting epithelial repair and Gus-expressing bacteria. Herein, we discovered that dehydrodiisoeugenol (DDIE), isolated from nutmeg, alleviates CPT11-induced intestinal mucositis alongside a synergistic antitumor effect with CPT11 by improving weight loss, colon shortening, epithelial barrier dysfunction, goblet cells and intestinal stem cells (ISCs) loss, and wound-healing. The anti-mucositis effect of DDIE is gut microbiota-dependent. Analysis of microbiome profiling data from clinical patients and CPT11-induced mucositis mice reveals a strong correlation between CPT11 chemotoxicity and Gus-expressing bacteria, particularly Enterococcus faecalis (E. faecalis). DDIE counters CPT11-induced augmentation of E. faecalis, leading to decreased intestinal Gus and SN38 levels. The Partial Least Squares Path Model (PLS-PM) algorithm initially links E. faecalis to dysregulated epithelial renovation. This is further validated in a 3D intestinal organoid model, in which both SN38 and E. faecalis hinder the formation and differentiation of organoids. Interestingly, colonization of E. faecalis exacerbates CPT11-induced mucositis and disturbs epithelial differentiation. Our study unveils a microbiota-driven, epithelial reconstruction-mediated action of DDIE against mucositis, proposing the 'Gus bacteria-host-irinotecan axis' as a promising target for mitigating CPT11 chemotoxicity.
Natural products that alleviate depression: The putative role of autophagy
Authors: Yunfeng Zhou, Fengwei Nan, Qianwen Zhang, Wangjun Xu, Shaojie Fang, Ke Liu, Bingxin Zhao, Hao Han, Xinmei Xie, Changjiang Qin, Xiaobin Pang
Journal: Pharmacology & Therapeutics (2024)
Microvascular obstruction in cardiac amyloidosis
Authors: Lucrezia Netti, Adam Ioannou, Ana Martinez‐Naharro, Yousuf Razvi, Aldostefano Porcari, Lucia Venneri, Viviana Maestrini, Dan Knight, Ruta Virsinskaite, Muhammad U. Rauf, Tushar Kotecha, Rishi K. Patel, Ashutosh Wechelakar, Helen Lachmann, Peter Kellman, Charlotte Manisty, James Moon, Philip N. Hawkins, Julian D. Gillmore, Marianna Fontana
Journal: European Journal of Heart Failure (2024)

Abstract Aims Cardiac amyloidosis (CA) is characterized by deposition of amyloid fibrils within the extracellular space, causing disarray of the myocardial structure and capillary architecture. This study aims to characterize the prevalence of microvascular obstruction (MVO) in patients with CA and to assess the association between MVO and prognosis. Methods and results The study population comprised 800 patients, of which 400 had light‐chain CA (AL‐CA) and 400 had transthyretin CA (ATTR‐CA). MVO was present in 221 (27.6%) patients, and more common in ATTR‐CA than AL‐CA (124 [56.1%] vs. 97 [43.9%], p = 0.033). Patients with MVO had a more severe cardiac phenotype evidenced by higher N‐terminal pro‐brain natriuretic peptide (3516 ng/L [1944–6247] vs. 2508 ng/L [1203–5752], p &lt; 0.001), worse global longitudinal strain (−10.5% [−12.6; −7.9] vs. −12.0% [−16.0; −8.9], p &lt; 0.001), and higher extracellular volume (56% [51–61] vs. 50% [45–57], p &lt; 0.001). Patients with AL‐CA and MVO had a higher serum troponin (86 ng/L [47–148] vs. 59 ng/L [44–78], p &lt; 0.001), and higher T2 (53 ms [50–56] vs. 50 ms [48–52], p &lt; 0.001), but lower extracellular volume (55% [50–60] vs. 58% [53–61], p = 0.008) and lower indexed myocyte cell volume (48.6 g/m 2 [41.1–59.8] vs. 55.7 g/m 2 [47.5–68.4], p &lt; 0.001) than patients with ATTR‐CA and MVO. MVO was associated with an increased risk of mortality in the overall population (hazard ratio [HR] 1.28, 95% confidence interval [CI] 1.03–1.59, p = 0.025), and the subgroup with AL‐CA (HR 1.59, 95% CI 1.17–2.17, p = 0.003) but not ATTR‐CA (HR 1.04, 95% CI 0.77–1.40, p = 0.814). Conclusions Microvascular obstruction is common in CA and is related to markers of amyloid infiltration. MVO is associated with an increased risk of mortality in AL‐CA, but not in ATTR‐CA. This reflects the intrinsic differences in disease biology between these two forms of CA, with MVO likely related to multiple myocardial processes, amyloid infiltration, oedema and myocyte death.
Platelets camouflaged nanovehicle improved bladder cancer immunotherapy by triggering pyroptosis
Authors: Jiale Tian, Mingde Gao, Jinfeng Zhu, Haifei Xu, Hao Ji, Donglin Xia, Xiaolin Wang
Journal: Theranostics (2024)

The regulation of immunosuppressive microenvironments in tumors through targeted drug delivery shows promise for immunochemotherapy in bladder cancer. Drawing inspiration from stealth tactics, a nano-vehicle camouflaged with platelets (PLTs) was developed to enable precise delivery and trigger pyroptosis for tumor immunotherapy.
PET imaging of microglia in Alzheimer's disease using copper-64 labeled TREM2 antibodies
Authors: Monireh Shojaei, Rebecca Schaefer, Kai Schlepckow, Lea H Kunze, Felix L Struebing, Bettina Brunner, Michael Willem, Laura M Bartos, Astrid Feiten, Giovanna Palumbo, Thomas Arzberger, Peter Bartenstein, Gian Carlo Parico, Dan Xia, Kathryn M Monroe, Christian Haass, Matthias Brendel, Simon Lindner
Journal: Theranostics (2024)

Triggering receptor expressed on myeloid cells 2 (TREM2) plays an essential role in microglia activation and is being investigated as a potential therapeutic target for modulation of microglia in several neurological diseases. In this study, we present the development and preclinical evaluation of
Spatial transcriptomic sequencing reveals immune microenvironment features of <i>Mycobacterium tuberculosis</i> granulomas in lung and omentum
Authors: Xiaochen Qiu, Pengfei Zhong, Liang Yue, Chaofan Li, Zhimin Yun, Guangqian Si, Mengfan Li, Zhi Chen, Yingxia Tan, Pengtao Bao
Journal: Theranostics (2024)

Granulomas are a key pathological feature of tuberculosis (TB), characterized by cell heterogeneity, spatial composition, and cellular interactions, which play crucial roles in granuloma progression and host prognosis. This study aims to analyze the transcriptome profiles of cell populations based on their spatial location and to understand the core transcriptome characteristics of granuloma formation and development.
Mitochondrial transfer balances cell redox, energy and metabolic homeostasis in the osteoarthritic chondrocyte preserving cartilage integrity
Authors: Angela C Court, Ana María Vega-Letter, Eliseo Parra-Crisóstomo, Francesca Velarde, Cynthia García, Alexander Ortloff, Rolando Vernal, Carolina Pradenas, Patricia Luz-Crawford, Maroun Khoury, Fernando E Figueroa
Journal: Theranostics (2024)

Osteoarthrosis (OA) is a leading cause of disability and early mortality, with no disease modifying treatment. Mitochondrial (MT) dysfunction and changes in energy metabolism, leading to oxidative stress and apoptosis, are main drivers of disease. In reaction to stress, mesenchymal stromal/stem cells (MSCs) donate their MT to damaged tissues.
Tau‑targeting multifunctional nanocomposite based on tannic acid-metal for near-infrared fluorescence/magnetic resonance bimodal imaging-guided combinational therapy in Alzheimer's disease
Authors: Yutian Gu, Qin Zhang, Honglin Huang, Kwun Hei Willis Ho, Yu Zhang, Changqing Yi, Yifan Zheng, Raymond Chuen Chung Chang, Emma Shujun Wang, Mo Yang
Journal: Theranostics (2024)

Alzheimer's disease (AD) is hallmarked by amyloid-β (Aβ) plaques and hyperphosphorylated tau (p-tau) neurofibrillary tangles. While Aβ-centric therapies have shown promise, the complex pathology of AD requires a multifaceted therapeutic approach. The weak association between Aβ levels and cognitive decline highlights the need for alternative theranostic strategies. Currently, oxidative stress and tau hyperphosphorylation are now recognized as critical pathological events in AD. Thus, therapies that concurrently attenuate oxidative stress damage and inhibit tau pathology hold great potential for AD treatment.
Real-time monitoring of single dendritic cell maturation using deep learning-assisted surface-enhanced Raman spectroscopy
Authors: Cai Zhang, Mengling Wang, Houde Wu, Hongmei Gao, Pengyun Wu, Li Guo, Dingbin Liu
Journal: Theranostics (2024)

Dynamic real-time detection of dendritic cell (DC) maturation is pivotal for accurately predicting immune system activation, assessing vaccine efficacy, and determining the effectiveness of immunotherapy. The heterogeneity of cells underscores the significance of assessing the maturation status of each individual cell, while achieving real-time monitoring of DC maturation at the single-cell level poses significant challenges. Surface-enhanced Raman spectroscopy (SERS) holds great potential for providing specific fingerprinting information of DCs to detect biochemical alterations and evaluate their maturation status.
Role of damaged mitochondrial transfer in alpha-particle generator <sup>212</sup>Pb radiation-induced bystander effect
Authors: Mengdie Yang, Lusheng Wang, Shanshan Qin, Xiongxin Dai, Jianguo Li, Liwei An, Lijuan Song, Jie Gao, Zongtai Han, Fei Yu
Journal: Theranostics (2024)

Pb, a promising
Single-cell profiling of brain pericyte heterogeneity following ischemic stroke unveils distinct pericyte subtype-targeted neural reprogramming potential and its underlying mechanisms
Authors: Allison Loan, Nidaa Awaja, Margarita Lui, Charvi Syal, Yiren Sun, Sailendra N Sarma, Ragav Chona, William B Johnston, Alex Cordova, Devansh Saraf, Anabella Nakhlé, Kaela O'Connor, Jacob Thomas, Joseph Leung, Matthew Seegobin, Ling He, Fredric E Wondisford, David J Picketts, Eve C Tsai, Hing Man Chan, Jing Wang
Journal: Theranostics (2024)

Brain pericytes can acquire multipotency to produce multi-lineage cells following injury. However, pericytes are a heterogenous population and it remains unknown whether there are different potencies from different subsets of pericytes in response to injury.
Brain-to-heart cholinergic synapse-calcium signaling mediates ischemic stroke-induced atrial fibrillation
Authors: Yingran Liang, Gongxin Wang, Siwen Fan, Junyi Zhang, Shuang He, Guixiang Pan, Guoliang Hao, Yan Zhu
Journal: Theranostics (2024)

Stroke-related cardiovascular diseases have attracted considerable attention, with atrial fibrillation (AF) being among the most frequent complications. Despite increasing clinical evidence, experimental models of stroke-induced AF are still lacking, hindering mechanistic discoveries and the development of adequate therapeutics targeting this stroke-heart syndrome (SHS). This study aims to create a rat model of ischemic stroke-induced AF (ISIAF) and to explore the efficacy and mechanism of Wenxin Keli (WK), an antiarrhythmic Chinese medicine.
Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies
Authors: Yu-Chen Zhang, Xian-Yang Li, Qi Deng, Yan-Jun Ge, Rui-Rong Yi, Hua-Jing Wang, Jian-Tao Wang, Hui Zhou, Xue-Feng Kong, Rong-Jiao Liu, Yu-Ting Zhang, Xiao-Pei Li, Xiao-Wen He, Hai-Yan Zhu
Journal: Theranostics (2024)

: CD39, a key ectonucleotidase that drives adenosine production, acts as a critical immunosuppressive checkpoint in cancer. Although it has shown promise as a therapeutic target, clinical trials are demonstrating the need for more potent targeting approaches. This need is driving innovation towards the development of novel antibodies and the exploration of strategic combinations with a range of immunotherapies.
Engineering mesenchymal stem cells for premature ovarian failure: overcoming challenges and innovating therapeutic strategies
Authors: Zijun Yuan, Yinping Zhang, Xinyu He, Xiang Wang, Xingyue Wang, Siqi Ren, Jiahong Su, Jing Shen, Xiang Li, Zhangang Xiao
Journal: Theranostics (2024)

Premature ovarian failure (POF) is a leading cause of infertility in women, causing significant psychological and physical distress. Current therapeutic options are limited, necessitating the exploration of new treatments. Mesenchymal stem cells (MSCs), known for their remarkable homing and regenerative properties, have emerged as a promising intervention for POF. However, their clinical efficacy has been inconsistent. This paper aims to address these challenges by examining the cellular heterogeneity within MSC populations, which is crucial for identifying and selecting specific functional subpopulations for clinical applications. Understanding this heterogeneity can enhance therapeutic efficacy and ensure treatment stability. Additionally, this review comprehensively examines the literature on the effectiveness, safety, and ethical considerations of MSCs for ovarian regeneration, with a focus on preclinical and clinical trials. We also discuss potential strategies involving genetically and tissue-engineered MSCs. By integrating insights from these studies, we propose new directions for the design of targeted MSC treatments for POF and related disorders, potentially improving outcomes, addressing safety concerns, and expanding therapeutic options while ensuring ethical compliance.
High-efficiency magnetophoretic labelling of adoptively-transferred T cells for longitudinal <i>in vivo</i> Magnetic Particle Imaging
Authors: Rong En Tay, Lokamitra P, Shun Toll Pang, Kay En Low, Hui Chien Tay, Charmaine Min Ho, Benoit Malleret, Olaf Rötzschke, Malini Olivo, Zhi Wei Tay
Journal: Theranostics (2024)

While adoptive cell therapies (ACT) have been successful as therapies for blood cancers, they have limited efficacy in treating solid tumours, where the tumour microenvironment excludes and suppresses adoptively transferred tumour-specific immune cells. A major obstacle to improving cell therapies for solid tumours is a lack of accessible and quantitative imaging modalities capable of tracking the migration and immune functional activity of ACT products for an extended duration
Harnessing glucose metabolism with nanomedicine for cancer treatment
Authors: Xudong Wang, Liping Wang, Qingyi Hao, Meng Cai, Xueting Wang, Wenlin An
Journal: Theranostics (2024)

The significance of metabolic processes in cancer biology has garnered substantial attention, as they are essential for meeting the anabolic demands and maintaining the redox balance of rapidly dividing cancer cells. A distinctive feature of tumors is that cancer cells, unlike normal cells, exhibit an increased rate of glucose metabolism. They predominantly relying on aerobic glycolysis to metabolize glucose, which enables these cells to supply energy and produce the necessary building blocks for growth. Targeting glucose metabolism has led to the development of various cancer treatments. However, these agents often have limited efficacy due to factors such as poor stability and solubility, rapid clearance and an insufficient amount of the drug reaching the target site. These limitations can be overcome by preparing nano dosage forms through nanotechnology, which leverages the unique properties of nanomaterials to deliver drugs more precisely to target tissues with controlled release. In this review, we provide a comprehensive overview of the latest advancements in nanomedicine, focusing on the modulation of glucose metabolism in cancer cells. We discuss the design and application of various strategies that have been engineered to target the metabolic hallmarks of cancer. These nanomedicine strategies aim to exploit the metabolic vulnerabilities of cancer cells, thereby offering novel approaches to cancer therapy. The review highlights the innovative nanomaterials and their potential to deliver therapeutic agents more effectively, as well as the challenges and considerations in translating these nanomedicines from bench to bedside. By targeting the glucose metabolism of cancer cells, these nanoscale interventions hold promise for improving treatment outcomes and potentially overcoming the resistance that often plagues conventional cancer therapies.